S-1: BioLargo Files for Resale of 34.9 Million Shares Issuable Upon Warrant Exercise

BioLargo, Inc. has filed a registration statement for the potential resale of up to 34,888,449 shares of its common stock by selling stockholders upon exercise of outstanding warrants.

Summary

• BioLargo, Inc., a cleantech company, has filed a Form S-1 registration statement with the SEC.
• The filing covers the potential resale of up to 34,888,449 shares of common stock by selling stockholders.
• These shares are issuable upon the exercise of warrants previously issued to the selling stockholders between May 4, 2020, and January 26, 2024, at an average exercise price of $0.2586 per share.
• BioLargo will not receive any proceeds from the sale of these shares by the selling stockholders, but may receive up to $9,022,461 in gross proceeds if all warrants are exercised.
• The company intends to use any proceeds from warrant exercises for working capital, debt repayment, and to fund the engineering, scale-up and commercialization of its technologies and products.
• As of the date of the prospectus, there were 295,803,576 shares of BioLargo's common stock outstanding.
• If all shares covered by the prospectus are issued, they would represent approximately 10.6% of the total outstanding shares and 12.1% of the total number of outstanding shares held by non-affiliates.
• The company's common stock is quoted on the OTC Markets OTCQB marketplace under the symbol BLGO.
• On April 11, 2024, the last reported sale price of BioLargo's common stock on the OTC Markets was $0.325.
• The prospectus highlights various risk factors associated with investing in BioLargo's common stock, including the company's history of net losses, need for additional financing, and the potential for dilution.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily providing factual information about the registration of shares for resale. While it highlights potential benefits from warrant exercises, it also acknowledges significant risks associated with investing in the company.

Positives

• Potential influx of $9,022,461 in gross proceeds if all warrants are exercised, strengthening the company's financial position.
• Proceeds from warrant exercises will be used to fund key initiatives, including technology commercialization and debt repayment.
• The company has a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering services.
• The company has a number of subsidiaries focused on different areas of cleantech.

Negatives

• The company will not receive any proceeds from the initial sale of shares by the selling stockholders.
• The exercise of warrants will dilute the ownership of existing stockholders.
• The company has incurred losses since inception and may continue to incur losses and negative cash flows in the future.
• The company's ability to access the capital markets to fund its operations could be limited due to factors beyond its control.

Risks

• The company has incurred losses since inception and may continue to incur losses and negative cash flows in the future.
• The company's cash requirements are significant, and it intends to continue to sell its securities to fund its operations, which is dilutive to current and future stockholders.
• The company's ability to access the capital markets to fund its operations could be limited due to factors beyond its control.
• The company has a limited operating history, which makes it difficult to forecast its future results.
• The recent increases in the company's revenues are due primarily to the marketing efforts of a third party that sells private-label odor-control products, and their efforts in the future are out of the company's control.
• The company's future success depends on its ability to retain and attract high-quality personnel, and the efforts, abilities and continued service of its senior management.
• The company may struggle to manage its growth effectively, and as a result its business may be harmed.
• Some of the company's products may require regulatory approval from the FDA or EPA.
• The company's internal disclosure controls and procedures over financial reporting are not effective, and could effect the accuracy of its financial statements.
• The company's common stock is currently a penny stock which trades on a limited basis on OTCQB, and due to factors beyond its control its stock price may be volatile.
• Trading in the company's common stock is limited, and future sales of its common stock may depress its stock price.

Future Outlook

The company expects to use any proceeds received from the exercise of the warrants to help fund the engineering, scale-up and commercialization of its technologies and products, including its battery and AEC PFAS-removal system; development of new products; marketing, sales and working capital for its subsidiaries; working capital for its engineering division; working capital for its research and development work; and working capital for its corporate operations.

Industry Context

The announcement relates to BioLargo's capital structure and potential funding for its cleantech operations, which are focused on addressing environmental problems like PFAS contamination and water pollution. The company operates in a competitive landscape with both established and emerging players in the environmental engineering and cleantech industries.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• The document mentions competitors such as Tesla, Clean Earth, Clean Harbors, Republic Services, Veolia and Covanta, but does not provide specific comparisons of financial performance or project results.

Stakeholder Impact

• Existing stockholders may experience dilution of their ownership if the warrants are exercised and the shares are sold.
• The company's financial position could be strengthened if the warrants are exercised and BioLargo receives the proceeds.
• The company's ability to execute its business plan could be enhanced if it receives the proceeds from the warrant exercises.

Next Steps

• Selling stockholders may offer and sell shares of common stock from time to time pursuant to the prospectus.
• BioLargo may receive proceeds from the exercise of warrants by the selling stockholders.
• BioLargo intends to use any proceeds received from warrant exercises for working capital, debt repayment, and to fund the commercialization of its technologies.

Key Dates

Keywords

BioLargo, common stock, warrants, resale, selling stockholders, registration statement, dilution, OTC Markets, BLGO, capital, proceeds, financial condition, risk factors